Under OXP treatment, the upregulation of IP-10 may contribute to chemoresistance through mechanisms that recruit immune-suppressive cells, such as MDSCs, which inhibit anti-tumor immune responses and support tumor survival [66,67]. Here, CXCL10 is linked to neoplasm.